Small Interfering RNA to Reduce Lipoprotein(a) in Cardiovascular DiseaseMichelle L. O’Donoghue, Marc S. Sabatine, Robert S. Rosenson et al.|New England Journal of Medicine|2022Cited by 513
Defining severe familial hypercholesterolaemia and the implications for clinical management: a consensus statement from the International Atherosclerosis Society Severe Familial Hypercholesterolemia PanelRaúl D. Santos, Shizuya Yamashita, Alberico L. Catapano et al.|The Lancet Diabetes & Endocrinology|2016Cited by 418
Evinacumab in Patients with Refractory HypercholesterolemiaRobert S. Rosenson, Daniel Gaudet, Lesley Burgess et al.|New England Journal of Medicine|2020Cited by 294
Vupanorsen, an N-acetyl galactosamine-conjugated antisense drug to <i>ANGPTL3</i> mRNA, lowers triglycerides and atherogenic lipoproteins in patients with diabetes, hepatic steatosis, and hypertriglyceridaemiaDaniel Gaudet, Ewa Karwatowska‐Prokopczuk, Seth J. Baum et al.|European Heart Journal|2020Cited by 276